Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Current Deferred Revenue (2020 - 2022)

Historic Current Deferred Revenue for Neuroone Medical Technologies (NMTC) over the last 3 years, with Q3 2022 value amounting to $1.5 million.

  • Neuroone Medical Technologies' Current Deferred Revenue rose 1677761.54% to $1.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $1.5 million, marking a year-over-year increase of 1677761.54%. This contributed to the annual value of $1.5 million for FY2022, which is 1677761.54% up from last year.
  • Latest data reveals that Neuroone Medical Technologies reported Current Deferred Revenue of $1.5 million as of Q3 2022, which was up 1677761.54% from $2248.0 recorded in Q2 2022.
  • Over the past 5 years, Neuroone Medical Technologies' Current Deferred Revenue peaked at $1.5 million during Q3 2022, and registered a low of $2248.0 during Q4 2021.
  • Moreover, its 3-year median value for Current Deferred Revenue was $11109.0 (2021), whereas its average is $195794.6.
  • As far as peak fluctuations go, Neuroone Medical Technologies' Current Deferred Revenue tumbled by 9560.59% in 2021, and later skyrocketed by 1677761.54% in 2022.
  • Quarter analysis of 3 years shows Neuroone Medical Technologies' Current Deferred Revenue stood at $51160.0 in 2020, then plummeted by 95.61% to $2248.0 in 2021, then surged by 64632.56% to $1.5 million in 2022.
  • Its Current Deferred Revenue was $1.5 million in Q3 2022, compared to $2248.0 in Q2 2022 and $2248.0 in Q1 2022.